NDAINTRAVENOUSPOWDERPriority Review
Approved
Sep 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
IDAMYCIN (idarubicin hydrochloride) by Pfizer is dna, inhibiting nucleic acid synthesis, inhibiting topoisomerase ii activity, and producing dna-damaging free radicals. First approved in 1990.
Drug data last refreshed 15h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IDAMYCIN (idarubicin hydrochloride) is a semi-synthetic anthracycline chemotherapy agent administered intravenously as a powder for reconstitution. It intercalates DNA, inhibits topoisomerase II, and generates DNA-damaging free radicals to disrupt nucleic acid synthesis. Primary use is in acute myeloid leukemia (AML) and other hematologic malignancies.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team restructuring and shift toward defense rather than growth.
Mechanism of Action
DNA, inhibiting nucleic acid synthesis, inhibiting topoisomerase II activity, and producing DNA-damaging free radicals.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on IDAMYCIN offers limited growth trajectory given LOE-approaching status and minimal linked job openings. Career value lies in managing a legacy oncology asset, defending market share, and potentially transitioning to combination or niche strategies before generic erosion accelerates.
Brand ManagerProduct Manager
Worked on IDAMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.